Digital Rights Watch wants AI scribes regulated as medical devices and patients given the right to refuse their use.
HEALTHCARE & FITNESS
Eli Lilly to Buy AtaiBeckley in Up to $3.8 Billion Psychedelic Drug Deal
Eli Lilly’s up to $3.8 billion acquisition of AtaiBeckley strengthens its push into psychedelic therapies, adding the late-stage depression treatment BPL-003 to its growing neuroscience portfolio.
Popular Reads
Category . Author
Story
Vertex Expands Rare Disease Portfolio With $10B Crinetics Buyout
The deal adds Crinetics' endocrine disease therapies to Vertex's pipeline and is expected to become accretive to adjusted operating income by 2029.
EchoIQ Lands $110 Million Backing for US Expansion of AI Cardiac Platform
The institutional placement will fund the growth of EchoIQ’s AI-enabled cardiovascular diagnostics business, building on its recent strategic partnership with Pro Medicus.
EU Panel Recommends Approval of Neuren’s Daybue
Neuren Pharmaceuticals has moved closer to European approval for its Rett syndrome treatment Daybue after receiving a positive recommendation from the EU's medicines regulator, paving the way for potential milestone payments and broader market access.
Gina Rinehart Backs Cancer Imaging Startup With $72 Mn Investment
Hancock Prospecting has invested $72 million in US-based Lumitron Technologies to support the commercialisation of advanced imaging technology designed to improve cancer detection and identify contaminants in mining operations.
More healthcare & fitness News
01
4D Medical Shares Fall Despite Winning Australian TGA Approval
4D Medical received Australian TGA approval for its CT:VQ lung imaging software, enabling immediate commercialisation. Despite the milestone, shares dropped 10.7% as the company also confirmed plans to seek Medicare reimbursement.
02
Ex-Organon Executive Meghan Rivera Joins Mayne Pharma Board
Mayne Pharma has appointed healthcare executive Meghan Rivera to its board, bringing experience from Organon, Akili Interactive and ViiV Healthcare.
03
Australian Watchdog Sues Miyagi Over Alleged Deceptive Health Practices
The Australian Competition and Consumer Commission (ACCC) has taken Sydney-based health company Miyagi to court, alleging sales staff posed as medical professionals and misled Australians about their health risks to sell expensive treatment programs.